SGLT2 inhibitors are an ‘effective’ treatment option for heart failure and type 2 diabetes

Sodium-glucose Cotransporter-2 (SGLT2) inhibitors demonstrated robust clinical effectiveness in older adults with heart failure and type 2 diabetes, latest research shows.

A new study suggests that SGLT2 inhibitors are better than sitagliptin for treating heart failure and type 2 diabetes in older people.

The aim of this trial was to evaluate the comparative effectives of SGLT2 inhibitors vs sitagliptin in older adults with the two conditions.

A team of researchers investigated whether there were any differences between agents within the SGLT2 inhibitors class or for reduced and preserved ejection fraction.

The findings state: “Initiation of SGLT2i vs. sitagliptin was associated with a lower risk of the primary composite outcome.

“The adjusted hazard ratios were 0.70 (0.63–0.78) for all-cause mortality, 0.64 (0.58–0.70) for hospitalisation for heart failure, and 0.77 (0.69–0.86) for urgent visit requiring intravenous diuretics.”

The results add: “Similar associations with the primary composite outcome were observed for all three agents within the SGLT2i class, for reduced and preserved ejection fraction, and subgroups based on demographics, comorbidities, and other heart failure treatments.

“Bias-calibrated hazard ratios for the primary endpoint using negative and positive control outcomes ranged between 0.81 and 0.89, suggesting that the observed benefit could not be fully explained by residual confounding.”

To read the full study, click here.